| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3275755 | Médecine des Maladies Métaboliques | 2010 | 5 Pages |
Abstract
A significant decline of cardiovascular risk has been obtained in patients with type 2 diabetes with statins. However, this cardiovascular risk remains high as compared to non diabetic individuals. This “cardiovascular residual risk”, in type 2 diabetes, is partly due to the typical abnormalities of diabetic dyslipidemia (hypertriglyceridemia, decreased HDL-cholesterol, small dense LDL particles) which are uncontrolled by statins and to atherogenic disorders associated with diabetes (chronic hyperglycemia, inflammation, oxidative stress). Reduction of this “cardiovascular residual risk” needs combined treatments to statins in order to correct the lipid abnormalities typical of diabetic dyslipidemia. However, the efficacy of such combined therapies to reduce significantly cardiovascular risk has still to be confirmed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Vergès,